Evaluation of the off-label usage of rituximab in a large teaching hospital in New South Wales.
Intern Med J
; 37(8): 569-71, 2007 Aug.
Article
en En
| MEDLINE
| ID: mdl-17640190
ABSTRACT
A retrospective review of patients receiving rituximab off label in a large teaching hospital was conducted between July 2002 and January 2006. The indication, dosing regimen, efficacy and cost of rituximab were evaluated. Rituximab was prescribed for three clinical indications; acute organ transplant rejection, post-transplant lymphoproliferative disease and autoimmune disease. On average, 600 mg of rituximab was prescribed weekly for 4 weeks, costing the hospital $108,739.37. We suggest an initial approval for a limited number of doses with subsequent approval dependent on improvement in predefined clinical or biochemical end-points. Furthermore, we suggest an Australia-wide central database be established to enable delineation of the optimal dosing schedule, as well as monitoring of clinical outcome.
Buscar en Google
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunosupresores
/
Anticuerpos Monoclonales
Límite:
Humans
País/Región como asunto:
Oceania
Idioma:
En
Revista:
Intern Med J
Asunto de la revista:
MEDICINA INTERNA
Año:
2007
Tipo del documento:
Article
País de afiliación:
Australia